Is there still a need for Tc-99m DMSA renal imaging?

Area of Science:

• Nuclear Medicine
• Diagnostic Imaging
• Renal Physiology

Background:

• Separate renal function (SRF) assessment is crucial for diagnosing and managing kidney disorders.
• Technetium-99m mercaptoacetyltriglycine (Tc-99m MAG3) scintigraphy is the current standard for SRF evaluation.
• Alternative scintigraphic methods warrant investigation for improved accuracy in specific patient populations.

Purpose of the Study:

• To compare the performance of Tc-99m MAG3 and Tc-99m dimercaptosuccinic acid (Tc-99m DMSA) scintigraphy for evaluating SRF.
• To determine the preferred scintigraphic method in patients with obesity or abnormal renal anatomy.

Main Methods:

• A comparative study involving 37 patients (12 children, 25 adults) with kidney disorders.
• All patients underwent both Tc-99m DMSA and Tc-99m MAG3 scintigraphy.
• Correlation analysis was performed between the two methods, stratified by weight and renal position.

Main Results:

• High correlation (r=0.99, P < 0.001) between Tc-99m MAG3 and Tc-99m DMSA for SRF in normal-weight patients.
• Lower correlation (r=0.82, P < 0.05) in overweight patients (>10% above Broca index) or those with abnormal renal positions.
• Tc-99m DMSA demonstrated superior accuracy in assessing renal parenchyma lesions.

Conclusions:

• Tc-99m DMSA scintigraphy is a more accurate method for SRF evaluation in overweight individuals.
• Tc-99m DMSA is preferable for SRF assessment in patients with abnormal kidney positions.
• Tc-99m DMSA offers advantages for evaluating renal parenchyma lesions compared to Tc-99m MAG3.